Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study

BACKGROUND: The NEJ026 Phase 3 study demonstrated that erlotinib and bevacizumab (BE)-treated NSCLC patients with EGFR mutations had significantly better progression-free survival (PFS) than those treated with erlotinib alone (E). This study included a prospective analysis of the relationship betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuhara, Tatsuro, Saito, Haruhiro, Furuya, Naoki, Watanabe, Kana, Sugawara, Shunichi, Iwasawa, Shunichiro, Tsunezuka, Yoshio, Yamaguchi, Ou, Okada, Prof Morihito, Yoshimori, Kozo, Nakachi, Ichiro, Gemma, Prof Akihiko, Azuma, Koichi, Kurimoto, Futoshi, Tsubata, Yukari, Fujita, Yuka, Nagashima, Hiromi, Asai, Gyo, Watanabe, Satoshi, Miyazaki, Masaki, Hagiwara, Prof Koichi, Nukiwa, Prof Toshihiro, Morita, Prof Satoshi, Kobayashi, Prof Kunihiko, Maemondo, Prof Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334809/
https://www.ncbi.nlm.nih.gov/pubmed/32629391
http://dx.doi.org/10.1016/j.ebiom.2020.102861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334809/
https://www.ncbi.nlm.nih.gov/pubmed/32629391
http://dx.doi.org/10.1016/j.ebiom.2020.102861

Ejemplares similares